NCT07332806 Site of Tracheal Extubation and Operating Room Efficiency During Robot-assisted Surgery
| NCT ID | NCT07332806 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Robotic Surgical Procedures |
| Study Type | INTERVENTIONAL |
| Enrollment | 218 participants |
| Start Date | 2026-01-12 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 218 participants in total. It began in 2026-01-12 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the impact of different extubation strategy on the occupancy time of operating room (OR) and the incidence of adverse events and quality of recovery after robotic-assisted surgery. The investigators hypothesize that extubation in the post-anesthesia care unit (PACU) may reduce OR occupancy time without increasing adverse events or worsening quality of recovery early after robotic-assisted surgery. This strategy may enhance perioperative efficiency while maintaining clinical safety.
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥18 years; 2. Scheduled to undergo elective robot-assisted laparoscopic surgery under general anesthesia; 3. Expected tracheal extubation during daytime working hours (before 4:00 PM). Exclusion Criteria: 1. Refuse to participate in the study; 2. Morbid obesity (body mass index ≥35 kg/m²); 3. Preoperatively diagnosed obstructive sleep apnea, or patients with a STOP-Bang score ≥3 in combination with serum bicarbonate (HCO₃-) ≥28 mmol/L; 4. Patients at high risk of difficult airway (anticipated difficult intubation and/or extubation during preoperative assessment); 5. Preexisting sick sinus syndrome, severe sinus bradycardia (heart rate \< 50 beats/min), or second-degree or higher atrioventricular block without pacemaker implantation; congenital heart disease with any type of arrhythmia; or other severe cardiovascular diseases with New York Heart Association (NYHA) functional class ≥III; 6. Significant pulmonary function impairment (FEV₁/FVC ratio \< 70%, and total lung capacity \[TLC\] and vital capacity \[VC\] \< 80% of predicted values); 7. Severe hepatic dysfunction (Child-Pugh class C); severe renal dysfunction (estimated glomerular filtration rate \< 30 mL/min/1.73 m²); or American Society of Anesthesiologists (ASA) physical status classification ≥IV; 8. Preoperative diagnoses of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis; 9. Inability to communicate due to coma, severe dementia, or language impairment; 10. Planned postoperative admission to the intensive care unit; 11. Any other conditions that are deemed for study participation.
Contact & Investigator
Dong-Xin Wang, MD, PhD
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT07332806 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Robotic Surgical Procedures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07332806 currently recruiting?
Yes, NCT07332806 is actively recruiting participants. Contact the research team at wangdongxin@hotmail.com for enrollment information.
Where is the NCT07332806 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07332806 clinical trial?
NCT07332806 is sponsored by Peking University First Hospital. The principal investigator is Dong-Xin Wang, MD, PhD at Peking University First Hospital. The trial plans to enroll 218 participants.